Results 211 to 220 of about 354,339 (315)

Understanding the Impact of Neighborhood Characteristics on Psychosis Risk Outcomes Through Shared and Distinct Pathways. [PDF]

Schizophr Bull
Ku BS, Arrant EJ, Walker EF.
europepmc   +1 more source

Language-Mediated Thought Blocking in a Bilingual Patient Diagnosed With Schizoaffective Disorder: A Case Report. [PDF]

Schizophr Res Cogn
Avilés SR.
europepmc   +1 more source

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source

Prevalence of anti-NMDA receptor antibodies among adult patients presenting with first-episode psychosis in Hong Kong. [PDF]

Schizophrenia (Heidelb)
Chau SWH, Lam CK, Yu MP, Choi JC, Leung HH.   +4 more
europepmc   +1 more source

Chloroquine Psychosis [PDF]

BMJ, 1966
openaire   +2 more sources

Psychiatric Disorders and Apathy in Mixed Movement Disorders Linked to ADCY5 (MxMD‐ADCY5)

Movement Disorders, EarlyView.
Abstract Background Mixed movement disorders linked to ADCY5 (MxMD‐ADCY5) represent a rare hyperkinetic movement disorder resulting from pathogenic variants in ADCY5. Psychiatric symptoms are suspected to be part of the phenotype. Objective The study aim was to assess psychiatric comorbidities in patients with MxMD‐ADCY5.
Aurélie Méneret, Clément Tarrano, Asya Ekmen, Diane Doummar, Victoria Gonzalez, Christine Tranchant, Mathieu Anheim, Philippe Damier, Eoin Mulroy, Kailash P. Bhatia, Laura Cif, Carlo Fusco, Miryam Carecchio, Norbert Brüggemann, Alexander Münchau, Florence Riant, Manon Gomes, Vanessa Brochard, Agathe Roubertie, Oriane Trouillard, Caroline Dubacq, Yulia Worbe, Mohamed Doulazmi, Emmanuel Roze   +23 more
wiley   +1 more source

Clozapine for treatment-resistant schizophrenia with epilepsy: A case report. [PDF]

PCN Rep
Horinouchi T, Mito M, Ishikawa T, Nakamura Y, Ishikawa S, Hashimoto N.   +5 more
europepmc   +1 more source

Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain

Movement Disorders, EarlyView.
Abstract Background Serotonergic and dopaminergic pathways are implicated in Parkinson's disease psychosis (PDP), but preliminary evidence also implicates the endocannabinoid system (ECS). Objectives We examined the association of gray matter volume loss in PDP patients with brain expression of the genes coding for CB1 (cannabinoid type 1) and CB2 ...
Sara Pisani, František Váša, Latha Velayudhan, Sagnik Bhattacharyya   +3 more
wiley   +1 more source

Specific psychiatric symptoms during cannabis use and their relation to psychotic disorders. [PDF]

Indian J Psychiatry
Buciuta A, Coman HG, Nemeș B, Oroian R, Lesinschi A, Caranfil N, Vică ML, Matei HV.   +7 more
europepmc   +1 more source